Targeted chronic myeloid leukemia therapy: Seeking a cure

Journal of Managed Care Pharmacy

Volumn 13, Issue 8 SUPPL. A, 2007, Pages

  Fausel, Christopher ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCR ABL; Imatinib; Interferon; Leukemia; Myelosuppression

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; BUSULFAN; CARBOPLATIN; CYTARABINE; DIURETIC AGENT; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOPORIN 98; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTHRALGIA; BLEEDING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER INHIBITION; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DEPRESSION; DISEASE COURSE; DOWNSTREAM PROCESSING; DRUG BINDING SITE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LIVING DONOR; LOW DRUG DOSE; LUNG FIBROSIS; MONOTHERAPY; MORTALITY; MYALGIA; NAUSEA; OVERALL SURVIVAL; PATIENT MONITORING; PERIORBITAL EDEMA; PHILADELPHIA 1 CHROMOSOME; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 36249015940     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s8-a.8     Document Type: Review

References (14)

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85-109.
2. Borgaonkar DS. Philadelphia-chromosome translocation and chronic myeloid leukaemia. Lancet. 1973;1:1250.
3. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064-77.
4. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994;84:4368-73.
5. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
6. Koziner B, Dengra C, Lucero G, et al. Autologous stem cell transplantation for patients with chronic myeloid leukemia. The Argentine Group of Bone Marrow Transplantation (GATMO) experience. Cancer. 2002;95:2339 45.
7. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084-86.
8. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-52.
9. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
10. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17.
11. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-37.
12. Amadori S, Picardi A, Fazi P, et al. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Leukemia. 1996;10:766-68.
13. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-39.
14. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637-47.